Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05292768
Starting soon Observational

Are Mast Cells Involved in Autoinflammatory Diseases

NCT05292768 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Started
2022-03
Last updated
2022-03-23

Condition(s) studied

Autoinflammatory DiseaseFMFTRAPSMKDCryopyrin Associated Periodic SyndromeHaploinsufficiency

Study summary

Autoinflammatory diseases (AID) are caused by innate immunity dysregulation. AID pathophysiology is only partly understood, especially in the case of unclassified AID. Mast cells (MC) are innate immune cells associated with a spectrum of disease between systemic mastocytosis and mast cell activation syndrome. The implication of MC has been shown in cryopyrin associated periodic syndrome (CAPS).Our aim is to evaluate the involvement of MC in AID by assessing clinical and biological signs of MC activation and studying cutaneous and digestive biopsies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients \>18 years old with Auto-inflammatory diseases already followed up at the CeRéMAIA (french national reference center for autoinflamamtory diseases and AA amyloidosis) of Tenon hospital and included in the JIRcohorte * Healthy adult controls, age- and sex-matched with MAI patients, and controls with mastocytosis, an immuno-inflammatory disease. * Subject affiliated to or entitled to a social security scheme * Collection of the patient's or healthy control's non-opposition Exclusion Criteria: * Subjects unable to answer questions or express themselves * Subjects who do not speak French * Subject deprived of liberty or under legal protection.

Primary outcome measure(s)

  • : presence of MCAS — at inclusion
    presence of clinical and biological markers of MCAS

Trial sites (1)

FacilityCityRegionStatus
Service de Médecine Interne Paris France

More Assistance Publique - Hôpitaux de Paris trials in France

Prospective Longitudinal Cohort Study of Vasculitis Patients Recruiting
Quality of Life of Caregivers Supporting an Older Adult With Cancer Starting soon
Study of the Prevalence of Endometriosis and Adenomyosis Recruiting
Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy Recruiting
Certolizumab in Recurrent Implantation Failure (RIF) Recruiting

Other trials for the same condition

Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases Recruiting
Unclassified GENotypes of Autoinflammatory Diseases and AA Amyloidosis Recruiting
Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases Recruiting
Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy Recruiting
Circadian Rhythm Deregulation in Patients With CAPS Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05292768 on ClinicalTrials.gov ↗ ← All trials in France